• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Incyte to Report First Quarter Financial Results

    4/10/25 8:00:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $INCY alert in real time by email

    Incyte (NASDAQ:INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 29, 2025.

    The schedule for the press release and conference call/webcast is as follows:

    • Q1 2025 Press Release: April 29, 2025 at 7:00 a.m. ET
    • Q1 2025 Conference Call: April 29, 2025 at 8:00 a.m. ET
    • Domestic Dial-In Number: 877-407-3042
    • International Dial-In Number: 201-389-0864
    • Conference ID Number: 13753168

    If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-7415. To access the replay you will need the conference ID number 13753168.

    The live webcast with slides can be accessed at Investor.Incyte.com and will be available for replay for ninety days.

    About Incyte

    A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

    For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250410696945/en/

    Media

    [email protected]



    Investors

    [email protected]

    Get the next $INCY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INCY

    DatePrice TargetRatingAnalyst
    6/16/2025$107.00Hold → Buy
    Stifel
    3/18/2025Buy → Neutral
    Guggenheim
    3/18/2025Outperform → Mkt Perform
    William Blair
    12/17/2024$77.00Neutral
    UBS
    10/29/2024$68.00 → $90.00Neutral → Buy
    BofA Securities
    10/1/2024$84.00Outperform
    Wolfe Research
    9/18/2024$83.00 → $74.00Buy → Hold
    Truist
    7/2/2024$52.00 → $48.00Market Perform → Underperform
    BMO Capital Markets
    More analyst ratings

    $INCY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Brawley Otis W was granted 2,518 shares, increasing direct ownership by 29% to 11,252 units (SEC Form 4)

      4 - INCYTE CORP (0000879169) (Issuer)

      6/12/25 4:31:17 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Fouse Jacqualyn A was granted 2,518 shares, increasing direct ownership by 15% to 19,326 units (SEC Form 4)

      4 - INCYTE CORP (0000879169) (Issuer)

      6/12/25 4:30:47 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Bienaime Jean Jacques was granted 2,518 shares, increasing direct ownership by 14% to 20,841 units (SEC Form 4)

      4 - INCYTE CORP (0000879169) (Issuer)

      6/12/25 4:30:12 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $INCY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

      QIAGEN to create a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies Companion diagnostic to identify key disease-causing mutations in patients with MPNs, with an initial focus on mutant CALR the second most common driver of MPNs Panel to be validated on Illumina NextSeq 550Dx platform for use with whole blood samples Partnership supports Incyte's extensive portfolio in myeloproliferative neoplasms, including INCA033989, and enhances QIAGEN's onco-hematology diagnostics pipeline QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) and Incyte (NASDAQ:INCY) today announced a ne

      6/15/25 4:00:00 AM ET
      $ILMN
      $INCY
      $QGEN
      Medical Specialities
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Positive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025

      Data demonstrates the potential for INCA033989 to modify disease by directly inhibiting and eliminating oncogenic mutCALR cells, while sparing healthy cells and restoring normal blood cell production In high-risk patients with essential thrombocythemia (ET) with a CALR mutation (mutCALR), 86% of INCA033989-treated patients at doses 400 mg and above achieved a complete or partial hematologic response with the majority (82%) realizing a complete response A reduction in peripheral blood mutCALR variant allele frequency (VAF) was observed in 89% of evaluable patients correlating with hematologic response Initial results demonstrate a favorable safety profile – no dose limiting toxicit

      6/15/25 3:15:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Phase 3 Data for Incyte's Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet

      POD1UM-303/InterAACT 2 is the first and largest global Phase 3 trial evaluating a PD-1 inhibitor in combination with chemotherapy for the treatment of patients with advanced SCAC not previously treated with systemic chemotherapy The trial met its primary endpoint; treatment with retifanlimab in combination with platinum-based chemotherapy (carboplatin-paclitaxel) resulted in clinically meaningful improvements in progression-free survival and overall survival In May 2025, the U.S. Food and Drug Administration (FDA) approved Zynyz® (retifanlimab-dlwr) in combination with carboplatin and paclitaxel and as a single agent for the treatment of advanced SCAC; submissions to other global

      6/12/25 6:45:00 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care